ARTICLES BY MATTHEW PILLAR

• Establishing A Research Function In Biopharma

  10/2/2023

  When it was time to double-down on development efforts to feed its pipeline of biologics, Horizon Therapeutics turned to Big Biopharma veteran Robert Stoffel, Ph.D. to lead the effort. Stoffel joined us for an episode of the Business of Biotech podcast to share how he did it.

• The DEI Value Proposition

  9/1/2023

  The value of DEI initiatives sometimes get lost in their feel-good, altruistic intent. Not at Rocket Pharmaceuticals, where purposeful and specific equity and inclusion exercises pay dividends in the form of a diverse, talented, and committed workforce. President & COO Kinnari Patel, PharmD explains.

• The Immigrant Approach To Biotech Formation

  8/1/2023

  Flagship Pioneering General Partner Avak Kahvejian, Ph.D., says successfully ideating new biotech companies — which Flagship has done in spades — requires the curiosity, skepticism, and paranoia of a new inhabitant in foreign land. Oh, and a little bit of machine learning won’t hurt.

• Inside M&A With Bill Symonds

  7/3/2023

  On episode 143 of the Business of Biotech, Enzyvant CEO Bill Symonds, Pharm.D. takes us inside the rationale and execution of last year’s Enzyvant/Altavant merger.

• Where Science Leads, Business Follows

  6/1/2023

  Learn how science, rather than market and investor expectations, directed Francois Rieger’s oversight of the Medsenic/Bone Therapeutics merger.

• The Hybrid Face Of Biopharma

  5/1/2023

  What came first, the development platform or the therapeutic asset? To a growing class of biotechs, it doesn’t even matter.

• Tech-Heavy Drug Discovery Yields Deep Pipeline

  4/3/2023

  The Business of Biotech caught up with Recursion Co-Founder & CEO Chris Gibson, Ph.D. on the heels of the company launching four clinical trials in just three quarters. That progress was built on a foundation of rapid, machine-enabled drug discovery.

• Why RNA Is Good For Business

  3/1/2023

  RNA’s not just good science, it’s good for business. No one understands this better than Nutcracker Therapeutics’ Dr. Geoff Nosrati, whose Ph.D. in Biochemistry and Molecular Biology supports him in his current role as Chief Business Officer at Nutcracker Therapeutics.

• Where Oncology Treatment Goes Next

  2/1/2023

  Dr. Steve Davidsen’s long tenure leading drug discovery efforts at AbbVie offers rare perspective into how far oncology treatment has come, and what’s needed to continue its progress.

• Anatomy Of A Biopharma VC Deal

  1/3/2023

  Ray Therapeutics CEO Paul Bresge and 4BIO Capital Managing Partner Dmitri Kuzmin, Ph.D. break down the deal that launched Ray and ponder the risk of a mission-driven biopharma CEO.

• The Rise Of Computational Biology In Biopharma

  12/1/2022

  I thought I’d peel a layer off the onion to reveal a trend that’s gaining momentum and having a positive impact during a somewhat negative biopharma news cycle: computational biology.

• Cashing In On Collaboration

  11/1/2022

  Our conversation with Philogen CEO, CSO, and Cofounder Prof. Dario Neri reveals his company’s metered emergence from academia, its avoidance of venture capital, and its rapid realization of revenue through pre-pipeline collaboration.

• What’s True Of Mice ≠ What’s True Of Men

  10/3/2022

  As ATMPs advance, scientists are calling out the limited value of mouse models in pharmacological research and testing. LIfT Biosciences’ Founder and CEO Alex Blyth is a vocal proponent of organoid/tumoroid models.

• The “Liberation” Of Science Yields A New Class Of Biopharma Leadership

  9/1/2022

  Purespring Therapeutics’ Richard Francis is among the dozens of Big Pharma executives who have defected to biopharma startups by riding the science, technology, and finance tides.

• Venture Philanthropy Launches Biotech From Within

  8/1/2022

  A summary of a discussion with Ben Yerxa, CEO of Opus Genetics, an early-stage gene therapy company launched in 2021 and in unique fashion on the back of the patient advocacy group the Retinal Degeneration Fund.